During 2021, Drug Delivery & Targeting (DDT) group continued working on the field of nanomedicine, developing novel therapeutic strategies based on biodegradable and natural nanovesicles. In 2021 DDT received funding from 15 projects (7 EU-funded), many of them developed in close collaboration with companies in the BioPharma field. Thanks to intense work, DDT has already become an international reference in use of extracellular vesicles as vehicles for lysosomal enzymes (JEV -IF 25.84), targeted polymeric micelles for delivery of small drugs and biomolecules (JCR, IF 978) and hydrogels for local treatment (MCEC, IF 7.33).
Addressing and proposing solutions for unmet clinical needs is one of our driving forces. Being able to move those solutions from the bench to the bedside, one of our biggest achievements. On 2021, we completed the EU-funded Nocanther project, that brought the first clinical study worldwide to treat locally advanced pancreatic cancer with iron oxide nanoparticles.
